A Phase 2 interventional study of LNA043 and Placebo in Osteoarthritis, sponsored by Novartis Pharmaceuticals. Completed at 19 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Osteoarthritis by Novartis — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Novartis.
Among the 26 studies in Osteoarthritis by Novartis, this one is the 17th largest by enrollment, is the only one that started in 2017, is one of 8 in phase 2, and was the 20th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →None of the 26 studies in Osteoarthritis by Novartis is open now. The open studies under Osteoarthritis, anywhere →
Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 320 across the 26 interventional studies. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Osteoarthritis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this two-part study is to assess the efficacy, safety and tolerability of multiple intra-articular (i.a.) injections of LNA043, in regenerating the articular surface in patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B).
There was a 30 day screening period for both Part A and Part B. In Part A, participants were randomized to 3:1 ratio and received an injection of LNA043 (20 mg in 3 ml) or matching placebo (3 ml) on Days 1, 8,15 and 22 and were monitored in clinic for 3 hours after each injection followed by telephone calls 48 hours after injection. Participants returned to the clinic on Days 50, 106, 190 and 365 for follow up visits. MRIs, safety assessments and pharmacokinetics were assessed at selected clinic visits.
In Part B, this study aimed at further evaluating the cartilage anabolic activity of LNA043 in a more severe knee OA population, and to explore the safety and efficacy of a higher dose.
In Part B, participants were randomized to LNA043 20 mg, LNA043 40 mg or matching placebo according in a 1:1:1 ratio. Injections were given in clinic on Days 1, 29, 57 and 85 and participants were monitored in clinic for 3 hours after each injection followed by telephone calls 48 hours after injection. Participants returned to the clinic on Days 113,197 and 365 (end of study) for follow up visits. MRIs, safety assessments and pharmacokinetics were assessed at selected clinic visits.
Inclusion criteria Part A
Inclusion criteria Part B
Exclusion criteria Part A \& B
Exclusion Criteria Part A only
Exclusion Criteria Part B only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LNA043 40 mg Part B
Biological: LNA043
LNA043 20 mg Part B
Biological: LNA043
LNA043 20 mg Part A
Biological: LNA043
Placebo Part A
Other: Placebo
Placebo Part B
Other: Placebo
LNA043 intra-articular injection
Placebo intra-articular injection
Change From Baseline in Articular Cartilage Collagen Organization in the Overall Cartilage (Femoral and Patellar Lesions) - Part A
Collagen fibril organization in articular cartilage evaluated by Magnetic Resonance Imaging (MRI) from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the focal cartilage lesion.
Time frame: Baseline up to Week 16, Week 28
Change From Baseline in Articular Cartilage Collagen Organization in the Deep Cartilage Layer (Femoral and Patellar Lesions) - Part A
Collagen fibril organization in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the focal cartilage lesion.
Time frame: Baseline up to Week 16, Week 28
Change From Baseline in Articular Cartilage Collagen Organization in the Superficial Cartilage Layer (Femoral and Patellar Lesions) - Part A
Collagen fibril organization in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality).The area of interest is the focal cartilage lesion.
Time frame: Baseline up to Week 16, Week 28
Change From Baseline of LNA043 to Placebo in Cartilage Volume in the Femoral Medial Index Region (mm3) - Part B
MRI based quantitative assessment using an automated segmentation algorithm
Time frame: Baseline, Week 29, Week 53
Change From Baseline of LNA043 to Placebo in Cartilage Thickness in the Femoral Medial Index Region (mm) - Part B
MRI based quantitative assessment using an automated segmentation algorithm.
Time frame: Baseline, Week 29, Week 53
Overview of Number of Participants With Adverse Events and Serious Adverse Events for Part A and Part B
Treatment emergent other and serious adverse events (TEAE and TESAE) period: Part A: Baseline up to Day 50 (included 30 day safety follow-up Part B: Baseline up to Day 113 (included 30 day safety follow-up) Long term Follow-UP period: Part A: Day 51 to Day 365 Part B: Day 114 to Day 365
Time frame: Baseline up to end of post treatment follow-up
Change From Baseline of LNA043 to Placebo in Cartilage Defect Volume (mm^3) for Both Groups of Patients (Femoral and Patellar Lesions) - Part A
Cartilage volume data were generated from the manual segmentation of the cartilage defect that was identified in MR images.
Time frame: Baseline up to Week 16, Week 28
Change From Baseline in Cartilage Mean T2 Relaxation Time as a Marker of Collagen Organization in the Medial Femoral Index Region - Overall Part B
Collagen fibril organisation in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the femoral medial index region comprising the anterior, central and posterior aspects of the femoral condyle.
Time frame: Baseline, Week 29, Week 53
Change From Baseline in Cartilage Mean T2 Relaxation Time as a Marker of Collagen Organization in the Medial Femoral Index Region - Deep Part B
Collagen fibril organisation in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the femoral medial index region comprising the anterior, central and posterior aspects of the femoral condyle.
Time frame: Baseline, Week 29, Week 53
Change From Baseline in Cartilage Mean T2 Relaxation Time as a Marker of Collagen Organization in the Medial Femoral Index Region - Superficial Part B
Collagen fibril organisation in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the femoral medial index region comprising the anterior, central and posterior aspects of the femoral condyle.
Time frame: Baseline, Week 29, Week 53
Incidence of Immunogenicity (IG) Part A
A validated ligand binding assay were used for the detection of anti-LNA043 antibodies, and cross-reactivity to ANGPTL3 and ANGPTL4.
Time frame: Week 1,3,8,16,28
Incidence of Immunogenicity (IG) Part B
A validated ligand binding assay were used for the detection of anti-LNA043 antibodies, and cross-reactivity to ANGPTL3 and ANGPTL4.
Time frame: Week 1,5,9,13,17,29,53
Serum Concentrations of LNA043 - Part A
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in serum. Concentrations below the LLOQ were reported as "zero"
Time frame: Week 1: 0 (pre-dose), 0.25 hours, 1, 2 hours post dose; Weeks 2, 3, 4: 0 hour (pre dose), 1 hour post dose
Serum Concentrations of ANGPTL3 - Part A
Validated bioanalytical assays were used to determine ANGPTL3 in serum with an LLOQ of 2.13 ng/mL. Concentrations below the LLOQ were reported as "zero"
Time frame: Week 1: 0 (pre-dose), 0.25 hours, 1, 2 hours post dose; Weeks 2, 3, 4: 0 hour (pre dose), 1 hour post dose
Synovial Fluid Concentrations of LNA043 - Part A
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in synovial fluid. Concentrations below the LLOQ were reported as "zero".
Time frame: Weeks 1,2,3,4: 0 hour (pre-dose)
Synovial Fluid Concentrations of ANGPTL3 - Part A
Validated bioanalytical assays were used to determine ANGPTL3 in synovial fluid with an LLOQ of 2.74 ng/mL. Concentrations below the LLOQ were reported as "zero".
Time frame: Weeks 1,2,3,4: 0 hour (pre-dose)
Serum Concentrations of LNA043 - Part B
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in serum. Concentrations below the LLOQ were reported as "zero
Time frame: Week 1: 0 (pre-dose), 2 hours post dose; Weeks 5 and 13: 1 hour post dose
Serum Concentrations of ANGPTL3 - Part B
Validated bioanalytical assays were used to determine ANGPTL3 in serum with an LLOQ of 2.13 ng/mL. Concentrations below the LLOQ were reported as "zero".
Time frame: Week 1: 0 (pre-dose), 2 hours post dose; Weeks 5 and 13: 1 hour post dose
Synovial Fluid Concentrations of LNA043 Part B
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in synovial fluid. Concentrations below the LLOQ were reported as "zero".
Time frame: Weeks 1,5.9.13: 0 hour (pre-dose)
Synovial Fluid Concentrations of ANGPTL3 - Part B
Validated bioanalytical assays were used to determine ANGPTL3 in synovial fluid with an LLOQ of 2.74 ng/mL. Concentrations below the LLOQ were reported as "zero".
Time frame: Weeks 1,5.9.13: 0 hour (pre-dose)
| Milestone | LNA043 20 mg Part A | Placebo Part A | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|---|---|
| Started | 43 | 15 | 27 | 27 | 29 |
| Patient d/c treatment but continued into follow up | 1 | 0 | 0 | 0 | 0 |
| Completed | 43 | 15 | 27 | 26 | 29 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Pi decision based on poor veins for blood sampling | 0 | 0 | 0 | 1 | 0 |
| Milestone | LNA043 20 mg Part A | Placebo Part A | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|---|---|
| Started | 43 | 15 | 27 | 26 | 29 |
| Completed | 42 | 15 | 24 | 25 | 28 |
| Not completed | 1 | 0 | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 1 |
| Withdrew: No longer required treatment | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject/guardian decision | 1 | 0 | 1 | 0 | 0 |
Collagen fibril organization in articular cartilage evaluated by Magnetic Resonance Imaging (MRI) from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the focal cartilage lesion.
| ms | LNA043 20 mg Part A | Placebo Part A |
|---|---|---|
| Week 16 | 3.02 ± 9.66 | 2.86 ± 16.31 |
| Week 28 | 5.59 ± 9.86 | 2.05 ± 15.91 |
Collagen fibril organization in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the focal cartilage lesion.
| ms | LNA043 20 mg Part A | Placebo Part A |
|---|---|---|
| Week 16 | -0.2 ± 8.18 | -2.20 ± 12.78 |
| Week 28 | 4.27 ± 8.68 | -3.17 ± 11.46 |
Collagen fibril organization in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality).The area of interest is the focal cartilage lesion.
| ms | LNA043 20 mg Part A | Placebo Part A |
|---|---|---|
| Week 16 n=17,7 | -13.05 ± 15.68 | -13.93 ± 24.73 |
| Week 28 n=16,9 | -10.45 ± 16.61 | -12.73 ± 22.09 |
MRI based quantitative assessment using an automated segmentation algorithm
| mm^3 | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 29 n=12,13,13 | 45.52 ± 61.90 | -12.79 ± 60.38 | -154.7 ± 60.25 |
| Week 53 n=11,13,7 | 75.54 ± 54.48 | -36.52 ± 51.21 | -152.7 ± 67.72 |
MRI based quantitative assessment using an automated segmentation algorithm.
| mm | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 29 n=12,13,13 | 0.01 ± 0.02 | 0.02 ± 0.02 | -0.04 ± 0.02 |
| Week 53 n=11,13,7 | -0.01 ± 0.02 | -0.00 ± 0.02 | -0.02 ± 0.03 |
Cartilage volume data were generated from the manual segmentation of the cartilage defect that was identified in MR images.
| mm^3 | LNA043 20 mg Part A | Placebo Part A |
|---|---|---|
| Week 16 | -2.55 ± 8.15 | -7.16 ± 13.55 |
| Week 28 | -11.97 ± 8.19 | -4.57 ± 13.36 |
Collagen fibril organisation in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the femoral medial index region comprising the anterior, central and posterior aspects of the femoral condyle.
| ms | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 29 n=21,21,25 | -1.59 ± 2.25 | -5.07 ± 2.26 | -4.97 ± 2.07 |
| Week 53 n=20,22,22 | -4.23 ± 2.29 | -10.53 ± 2.25 | -3.09 ± 2.18 |
Collagen fibril organisation in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the femoral medial index region comprising the anterior, central and posterior aspects of the femoral condyle.
| ms | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 29 n=21,21,25 | -3.80 ± 2.47 | -5.07 ± 2.49 | -5.89 ± 2.26 |
| Week 53 n=20,22,22 | -3.93 ± 2.53 | -12.17 ± 2.54 | -6.21 ± 2.41 |
Collagen fibril organisation in articular cartilage evaluated by MRI from the cartilage mean T2 relaxation time (with lower values indicative of higher quality). The area of interest is the femoral medial index region comprising the anterior, central and posterior aspects of the femoral condyle.
| ms | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 29 n=21,21,25 | -0.06 ± 2.51 | -4.16 ± 2.51 | -3.53 ± 2.30 |
| Week 53 n=20,22,22 | -3.54 ± 2.36 | -9.07 ± 2.36 | -0.91 ± 2.25 |
A validated ligand binding assay were used for the detection of anti-LNA043 antibodies, and cross-reactivity to ANGPTL3 and ANGPTL4.
| participants | LNA043 20 mg Part A | Placebo Part A |
|---|---|---|
| Week 1 (Day 1) Predose | 0 | 0 |
| Week 3 (Day 15) Pre-dose | 0 | 0 |
| Week 8 (Day 50) | 0 | 0 |
| Week 16 (Day 106) | 0 | 0 |
| Week 28 (Day 190) | 0 | 0 |
A validated ligand binding assay were used for the detection of anti-LNA043 antibodies, and cross-reactivity to ANGPTL3 and ANGPTL4.
| participants | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 1 (Day 1) Predose | 0 | 0 | 0 |
| Week 5 Pre-dose | 0 | 0 | 0 |
| Week 9 | 0 | 0 | 0 |
| Week 13 | 0 | 0 | 0 |
| Week 17 | 0 | 0 | 0 |
| Week 29 | 0 | 0 | 0 |
| Week 53 | 0 | 0 | 0 |
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in serum. Concentrations below the LLOQ were reported as "zero"
| ng/mL | LNA043 20 mg Part A |
|---|---|
| Week 1, 0 hour pre-dose | 0 ± 0 |
| Week 1, 0.25 hour post dose n=6 | 24.9 ± 16.3 |
| Week 1, 1 hour post dose n=7 | 65.1 ± 30.2 |
| Week 1, 2 hours post dose n=41 | 64.9 ± 37.5 |
| Week 2,0 hour pre dose n=42 | 0.00 ± 0.00 |
| Week 2, 1 hour post dose n=43 | 48.1 ± 32.9 |
| Week 3, 0 hour pre dose n=41 | 0.00 ± 0.00 |
| Week 3, 1 hour post dose n=39 | 51.0 ± 37.6 |
| Week 4, 0 hour pre dose n=42 | 3.00 ± 19.4 |
| Week 4, 1 hour post dose n=41 | 52.9 ± 38.1 |
Validated bioanalytical assays were used to determine ANGPTL3 in serum with an LLOQ of 2.13 ng/mL. Concentrations below the LLOQ were reported as "zero"
| ng/mL | LNA043 20 mg Part A | Placebo Part A |
|---|---|---|
| Week 1, 0 hour pre-dose n=41,14 | 19.1 ± 9.29 | 23.3 ± 8.55 |
| Week 1, 0.25 hour post dose n=6,2 | 20.8 ± 8.12 | 20.4 ± 6.36 |
| Week 1, 1 hour post dose n=7,2 | 19.7 ± 8.65 | 18.2 ± 3.32 |
| Week 1, 2 hours post dose n=40,15 | 18.9 ± 9.38 | 24.3 ± 9.52 |
| Week 2,0 hour pre dose n=42,15 | 18.9 ± 10.3 | 21.7 ± 10.2 |
| Week 2, 1 hour post dose n=42,15 | 18.3 ± 8.06 | 19.7 ± 9.58 |
| Week 3, 0 hour pre dose n=42,14 | 19.1 ± 7.79 | 24.2 ± 9.95 |
| Week 3, 1 hour post dose n=39,14 | 18.5 ± 7.35 | 28.9 ± 16.4 |
| Week 4, 0 hour pre dose n=42,15 | 19.6 ± 8.71 | 21.0 ± 7.11 |
| Week 4, 1 hour post dose n=41,15 | 19.6 ± 7.87 | 22.6 ± 9.06 |
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in synovial fluid. Concentrations below the LLOQ were reported as "zero".
No measurements were reported for this outcome.
Validated bioanalytical assays were used to determine ANGPTL3 in synovial fluid with an LLOQ of 2.74 ng/mL. Concentrations below the LLOQ were reported as "zero".
| ng/mL | LNA043 20 mg Part A | Placebo Part A |
|---|---|---|
| Week 1, 0 hour pre-dose n=8,3 | 0.00 ± 0.00 | 00.0 ± 00.0 |
| Week 2,0 hour pre dose n=11,5 | 0.00 ± 0.00 | 00.0 ± 00.0 |
| Week 3, 0 hour pre dose n=13,4 | 0.616 ± 2.22 | 00.0 ± 00.0 |
| Week 4, 0 hour pre dose n=15,3 | 1.42 ± 5.50 | 00.0 ± 00.0 |
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in serum. Concentrations below the LLOQ were reported as "zero
| ng/mL | LNA043 20 mg Part B | LNA043 40 mg Part B |
|---|---|---|
| Week 1, 0 hours pre-dose n=27,26 | 3.48 ± 18.1 | 7.96 ± 40.6 |
| Week 1, 2 hours post dose n=24,24, | 76.4 ± 51.0 | 158 ± 94.0 |
| Week 5, 1 hour post dose n=27,26 | 55.6 ± 47.0 | 101 ± 74.2 |
| Week 13, 1 hour post dose n=27,25 | 59.5 ± 53.0 | 118 ± 78.2 |
Validated bioanalytical assays were used to determine ANGPTL3 in serum with an LLOQ of 2.13 ng/mL. Concentrations below the LLOQ were reported as "zero".
| ng/mL | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 1, 0 hour pre-dose n=27,26,29 | 25.3 ± 11.1 | 21.9 ± 9.09 | 26.6 ± 14.0 |
| Week 1, 2 hours post dose n=24,24,26 | 26.0 ± 12.8 | 23.9 ± 10.6 | 27.6 ± 13.1 |
| Week 5, 1 hour post dose n=26,26,28 | 21.8 ± 9.80 | 23.3 ± 9.97 | 26.2 ± 10.8 |
| Week 13, 1 hour post dose n=27,25,28 | 22.9 ± 8.72 | 22.5 ± 8.39 | 24.8 ± 11.8 |
Concentrations for LNA043 were determined by a validated LC-MS/MS method; the anticipated LLOQ was 10ng/mL in synovial fluid. Concentrations below the LLOQ were reported as "zero".
| ng/mL | LNA043 20 mg Part B | LNA043 40 mg Part B |
|---|---|---|
| Week 1, 0 hours pre dose n=9,5 | 28.9 ± 86.7 | 0.00 ± 0.00 |
| Week 5, 0 hours pre dose n=10,5 | 368 ± 1160 | 18.1 ± 40.6 |
| Week 9, 0 hours pre-dose n=11,6 | 0.00 ± 0.00 | 43600 ± 90900 |
| Week 13, 0 hours pre dose n=8,4 | 0.00 ± 0.00 | 199000 ± 398000 |
Validated bioanalytical assays were used to determine ANGPTL3 in synovial fluid with an LLOQ of 2.74 ng/mL. Concentrations below the LLOQ were reported as "zero".
| ng/mL | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B |
|---|---|---|---|
| Week 1, 0 hour pre-dose n=8,3,8 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| 0.00Week 5,,0 hour pre dose n=10,5,12 | 1.00 ± 3.16 | 4.38 ± 9.79 | 1.57 ± 5.43 |
| Week 9,, 0 hour pre dose n=8,4,9 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 13, 0 hour pre dose n=7,4,8 | 0.00 ± 0.00 | 1.87 ± 3.74 | 0.890 ± 2.52 |
Treatment emergent other and serious adverse events (TEAE and TESAE) period: Part A: Baseline up to Day 50 (included 30 day safety follow-up Part B: Baseline up to Day 113 (included 30 day safety follow-up) Long term Follow-UP period: Part A: Day 51 to Day 365 Part B: Day 114 to Day 365
| participants | LNA043 20 mg Part A | Placebo Part A | LNA043 20 mg Part B | LNA043 40mg Part B | Placebo Part B |
|---|---|---|---|---|---|
| Part A TEAE | 19 | 7 | — | — | — |
| Part A TESAE | 0 | 0 | — | — | — |
| Part A - Follow-up AE | 16 | 1 | — | — | — |
| Part A - Follow-up SAE | 2 | 0 | — | — | — |
| Part B - TEAE | — | — | 6 | 15 | 10 |
| Part B - TESAE | — | — | 1 | 0 | 0 |
| Part B - Follow-up AE | — | — | 3 | 5 | 12 |
| Part B - Follow-up SAE | — | — | 1 | 0 | 2 |
Collected over Treatment emergent (TE) averse events: Part A: Baseline up to Day 50 (including 30 day safety follow-up post last dose) Part B: Baseline up to Day 113 (including 30 day safety follow-up post last dose) Long term Follow-Up (FU) period: Part A: Day 51 to Day 365 Part B: Day 114 to Day 365. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LNA043 20 mg Part A - TE | 0/43 (0%) | 0/43 (0%) | 19/43 (44.2%) |
| Placebo Part A - TE | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| LNA043 20 mg Part B - TE | 0/27 (0%) | 1/27 (3.7%) | 6/27 (22.2%) |
| LNA043 40 mg Part B - TE | 0/27 (0%) | 0/27 (0%) | 15/27 (55.6%) |
| Placebo Part B - TE | 0/29 (0%) | 0/29 (0%) | 10/29 (34.5%) |
| LNA043 20 mg Part A - FU | 0/43 (0%) | 2/43 (4.7%) | 16/43 (37.2%) |
| Placebo Part A - FU | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| LNA043 20 mg Part B - FU | 0/27 (0%) | 1/27 (3.7%) | 3/27 (11.1%) |
| LNA043 40 mg Part B - FU | 0/27 (0%) | 0/27 (0%) | 5/27 (18.5%) |
| Placebo Part B - FU | 0/29 (0%) | 2/29 (6.9%) | 12/29 (41.4%) |
| Event | LNA043 20 mg Part A - TE | Placebo Part A - TE | LNA043 20 mg Part B - TE | LNA043 40 mg Part B - TE | Placebo Part B - TE | LNA043 20 mg Part A - FU | Placebo Part A - FU | LNA043 20 mg Part B - FU | LNA043 40 mg Part B - FU | Placebo Part B - FU |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/43 | 0/15 | 1/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 1/27 | 0/27 | 0/29 |
| Blood loss anaemiaBlood and lymphatic system disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 1/29 |
| Colitis ischaemicGastrointestinal disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 1/29 |
| Deep vein thrombosisVascular disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 1/29 |
| Vena cava thrombosisVascular disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 1/29 |
| Odontogenic cystCongenital, familial and genetic disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 1/43 | 0/15 | 0/27 | 0/27 | 0/29 |
| Back painMusculoskeletal and connective tissue disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 1/43 | 0/15 | 0/27 | 0/27 | 0/29 |
| Event | LNA043 20 mg Part A - TE | Placebo Part A - TE | LNA043 20 mg Part B - TE | LNA043 40 mg Part B - TE | Placebo Part B - TE | LNA043 20 mg Part A - FU | Placebo Part A - FU | LNA043 20 mg Part B - FU | LNA043 40 mg Part B - FU | Placebo Part B - FU |
|---|---|---|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/43 | 1/15 | 1/27 | 4/27 | 1/29 | 3/43 | 0/15 | 0/27 | 2/27 | 2/29 |
| HeadacheNervous system disorders | 6/43 | 1/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 |
| Joint swellingMusculoskeletal and connective tissue disorders | 4/43 | 0/15 | 1/27 | 1/27 | 3/29 | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 |
| Blood uric acid increasedInvestigations | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 2/27 | 0/29 |
| Abdominal painGastrointestinal disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 1/27 | 2/29 |
| HaemorrhoidsGastrointestinal disorders | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 2/29 |
| COVID-19Infections and infestations | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 2/29 |
| Blood creatine phosphokinase increasedInvestigations | 1/43 | 0/15 | 1/27 | 1/27 | 0/29 | 0/43 | 0/15 | 0/27 | 1/27 | 2/29 |
| Dental cariesGastrointestinal disorders | 0/43 | 1/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 |
| GastroenteritisInfections and infestations | 0/43 | 1/15 | 0/27 | 0/27 | 0/29 | 0/43 | 0/15 | 0/27 | 0/27 | 0/29 |
| Age, Customized(participants) | LNA043 20 mg Part A | Placebo Part A | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B | Total |
|---|---|---|---|---|---|---|
| ≥18 and ≤55 years Part A only | 43 | 15 | — | — | — | 58 |
| ≥18 and ≤64 Part B only | — | — | 18 | 15 | 15 | 48 |
| ≥65 and ≤76 years - Part B only | — | — | 9 | 12 | 14 | 35 |
| Sex: Female, Male(Participants) | LNA043 20 mg Part A | Placebo Part A | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B | Total |
|---|---|---|---|---|---|---|
| Female | 21 | 5 | 19 | 20 | 21 | 86 |
| Male | 22 | 10 | 8 | 7 | 8 | 55 |
| Race/Ethnicity, Customized(participants) | LNA043 20 mg Part A | Placebo Part A | LNA043 20 mg Part B | LNA043 40 mg Part B | Placebo Part B | Total |
|---|---|---|---|---|---|---|
| Asian | 1 | 1 | 0 | 0 | 1 | 3 |
| White | 42 | 11 | 20 | 26 | 24 | 123 |
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African | 0 | 1 | 7 | 1 | 3 | 12 |
| American Unknow | 0 | 1 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Sep 2017 to primary completion in Sep 2022, 59 months.
Results were first posted in Feb 2024, 1 year 5 months after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 59 months is above that.
Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LNA043